CD274 and tuberculosis: The success of immune checkpoint therapies that reinvigorate immune responses in cancer therapy, such as those targeting PD-1/PDL-1 (49), has prompted a search for immune cell inhibitory receptors that trigger immunosuppressive signaling pathways during M. tuberculosis pathogenesis (50) for development as similar therapeutic targets for TB.